ClinVar Miner

Submissions for variant NM_000466.3(PEX1):c.2926+1G>A

gnomAD frequency: 0.00006  dbSNP: rs267608179
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000599041 SCV000340724 pathogenic not provided 2016-03-25 criteria provided, single submitter clinical testing
GeneDx RCV000599041 SCV000709922 pathogenic not provided 2023-01-23 criteria provided, single submitter clinical testing Canonical splice site variant predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 9398847, 16086329, 9398848, 16141001, Parsamanesh2021[Case Report], 21031596, 15542397, 19105186)
Invitae RCV002228604 SCV000963840 pathogenic Zellweger spectrum disorders 2023-12-21 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 18 of the PEX1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PEX1 are known to be pathogenic (PMID: 21031596, 26387595, 31831025). This variant is present in population databases (rs267608179, gnomAD 0.005%). Disruption of this splice site has been observed in individuals with Zellweger syndrome spectrum disorders (PMID: 15542397, 19105186, 21031596). ClinVar contains an entry for this variant (Variation ID: 188729). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that disruption of this splice site affects PEX1 function (PMID: 9398847). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001194281 SCV001363681 pathogenic Peroxisome biogenesis disorder 2019-10-18 criteria provided, single submitter clinical testing Variant summary: PEX1 c.2926+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Three predict that the variant abolishes a 5 prime splicing donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing (e.g. Reuber_1997). The variant allele was found at a frequency of 2e-05 in 251300 control chromosomes (gnomAD). c.2926+1G>A has been reported in the literature in individuals affected with Zellweger Syndrome spectrum disorder (e.g. Steinberg_2004, Reuber_1997, Yik_2009, Ebberink_2010) . These data indicate that the variant is likely to be associated with disease. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Baylor Genetics RCV001332473 SCV001524807 pathogenic Peroxisome biogenesis disorder 1B 2019-12-17 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
Myriad Genetics, Inc. RCV001810430 SCV002060375 likely pathogenic Peroxisome biogenesis disorder 1A (Zellweger); Peroxisome biogenesis disorder 1B 2021-11-10 criteria provided, single submitter clinical testing NM_000466.2(PEX1):c.2926+1G>A is a canonical splice variant classified as likely pathogenic in the context of peroxisome biogenesis disorder type 1. c.2926+1G>A has been observed in cases with relevant disease (PMID: 19105186, 15542397). Functional assessments of this variant are available in the literature (PMID: 9398847). c.2926+1G>A has been observed in population frequency databases (gnomAD NFE 0.004%). In summary, NM_000466.2(PEX1):c.2926+1G>A is a canonical splice variant in a gene where loss of function is a known mechanism of disease, is predicted to disrupt protein function, and has been observed more frequently in cases with the relevant disease than in healthy populations. Please note: this variant was assessed in the context of healthy population screening.
Ambry Genetics RCV002516527 SCV003548279 likely pathogenic Inborn genetic diseases 2021-11-05 criteria provided, single submitter clinical testing The c.2926+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 18 of the PEX1 gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on data from gnomAD, the A allele has an overall frequency of <0.01% (7/282690) total alleles studied. This variant has been reported in individuals with PEX1-related peroxisome biogenesis spectrum disorder, including one compound heterozygous individual and one individual with no reported second variant (Reuber, 1997; Portsteffen, 1997; Yik, 2009). In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, this alteration is classified as likely pathogenic.
Baylor Genetics RCV003474896 SCV004203267 pathogenic Heimler syndrome 1 2023-10-18 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.